S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands

Cocrystal Pharma (COCP) Competitors

$1.43
-0.03 (-2.05%)
(As of 02/29/2024 ET)

COCP vs. PPBT, AGE, RNXT, MIRA, NNVC, RDHL, AYTU, PIRS, GRTX, and VBIV

Should you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Purple Biotech (PPBT), AgeX Therapeutics (AGE), RenovoRx (RNXT), MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), RedHill Biopharma (RDHL), Aytu BioPharma (AYTU), Pieris Pharmaceuticals (PIRS), Galera Therapeutics (GRTX), and VBI Vaccines (VBIV). These companies are all part of the "pharmaceutical preparations" industry.

Cocrystal Pharma vs.

Cocrystal Pharma (NASDAQ:COCP) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.

Purple Biotech's return on equity of -46.74% beat Cocrystal Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cocrystal PharmaN/A -54.10% -51.18%
Purple Biotech N/A -46.74%-40.84%

Purple Biotech is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cocrystal PharmaN/AN/A-$38.84M-$2.10-0.68
Purple BiotechN/AN/A-$21.67M-$1.06-0.80

Cocrystal Pharma has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Cocrystal Pharma received 9 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 90.91% of users gave Purple Biotech an outperform vote while only 73.08% of users gave Cocrystal Pharma an outperform vote.

CompanyUnderperformOutperform
Cocrystal PharmaOutperform Votes
19
73.08%
Underperform Votes
7
26.92%
Purple BiotechOutperform Votes
10
90.91%
Underperform Votes
1
9.09%

Cocrystal Pharma currently has a consensus target price of $10.00, suggesting a potential upside of 599.30%. Purple Biotech has a consensus target price of $9.00, suggesting a potential upside of 965.85%. Given Purple Biotech's higher possible upside, analysts plainly believe Purple Biotech is more favorable than Cocrystal Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cocrystal Pharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Purple Biotech
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Purple Biotech had 3 more articles in the media than Cocrystal Pharma. MarketBeat recorded 6 mentions for Purple Biotech and 3 mentions for Cocrystal Pharma. Purple Biotech's average media sentiment score of 0.46 beat Cocrystal Pharma's score of 0.29 indicating that Purple Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cocrystal Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Purple Biotech
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

13.4% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 7.2% of Purple Biotech shares are owned by institutional investors. 25.1% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Purple Biotech beats Cocrystal Pharma on 9 of the 14 factors compared between the two stocks.


Get Cocrystal Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COCP vs. The Competition

MetricCocrystal PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$14.54M$6.70B$4.91B$7.51B
Dividend YieldN/A2.80%2.90%3.86%
P/E Ratio-0.6814.56256.5218.26
Price / SalesN/A1,191.143,327.60306.83
Price / Cash8.8119.5296.1854.73
Price / Book0.294.814.454.54
Net Income-$38.84M$158.84M$114.26M$211.48M
7 Day Performance-0.69%5.09%4.23%2.61%
1 Month Performance-12.27%12.01%8.77%5.45%
1 Year Performance-25.52%5.61%12.18%8.65%

Cocrystal Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PPBT
Purple Biotech
2.9459 of 5 stars
$0.67
-5.6%
$9.00
+1,242.1%
-57.8%$14.77MN/A-0.6320Upcoming Earnings
Analyst Report
High Trading Volume
AGE
AgeX Therapeutics
0 of 5 stars
$0.39
+5.4%
N/A-35.4%$14.79M$30,000.00-1.055News Coverage
RNXT
RenovoRx
1.2825 of 5 stars
$1.31
-4.4%
$8.50
+548.9%
-63.0%$14.00MN/A-1.3910Upcoming Earnings
Short Interest ↑
Gap Down
MIRA
MIRA Pharmaceuticals
0.3263 of 5 stars
$1.05
+1.9%
N/AN/A$15.52MN/A0.002Short Interest ↑
Gap Up
NNVC
NanoViricides
0 of 5 stars
$1.33
flat
$5.25
+294.7%
-2.4%$15.67MN/A-1.647Analyst Report
Gap Down
RDHL
RedHill Biopharma
0 of 5 stars
$0.53
flat
N/A-93.2%$15.72M$61.80M0.00113Short Interest ↓
News Coverage
Positive News
AYTU
Aytu BioPharma
3.2196 of 5 stars
$2.84
-1.7%
$5.00
+76.1%
+8.6%$15.82M$107.40M-0.70150Short Interest ↑
PIRS
Pieris Pharmaceuticals
2.9544 of 5 stars
$0.16
-5.9%
N/A-89.0%$15.88M$25.90M-0.46127Short Interest ↓
GRTX
Galera Therapeutics
1.1669 of 5 stars
$0.25
+31.6%
$9.00
+3,498.6%
-86.3%$13.60MN/A-0.1331Gap Down
High Trading Volume
VBIV
VBI Vaccines
1.463 of 5 stars
$0.57
-1.7%
N/A-94.0%$13.39M$1.08M-0.05190Analyst Report

Related Companies and Tools

This page (NASDAQ:COCP) was last updated on 3/1/2024 by MarketBeat.com Staff